GovWire

Research: Public Assessment Report of the reclassification of Sudafed Plus Blocked Nose 1mg/50mg/ml Nasal Spray Solution

Medicines Healthcare Products Regulatory Agency

August 3
10:13 2022

Sudafed Plus Blocked Nose 1mg/50mg/ml Nasal Spray Solution - Pubic Assessment Report (PAR)

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email webupdates@mhra.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Sudafed Plus Blocked Nose 1mg/50mg/ml nasal spray solution can be used for the symptomatic relief of nasal congestion associated with the common cold, influenza, sinusitis, allergic and non-allergic rhinitis (vasomotor rhinitis), other upper respiratory tract allergies in adults and children aged 12 years and over.

Sudafed Plus Blocked Nose 1mg/50mg/ml nasal spray solution contains xylometazoline hydrochloride 1mg/ml (0.1% w/v) and dexpanthenol 50mg/ml (5% w/v).

The marketing authorisation holder, McNeil Products Limited, applied to change the legal status of this product from Prescription Only Medicine (POM) to a Pharmacy (P) medicine.

The Medicines and Healthcare Products Regulatory Agency (MHRA) considers this product sufficiently safe to be sold as a pharmacy medicine. This report outlines the evidence that the MHRA reviewed and which led to the decision to approve the application.

Published 3 August 2022

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: